SEC
IMVT icon

Seven Eight Capital’s Immunovant IMVT Stock Holding History

Seven Eight Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,575
Closed -$279K – 833
2024
Q2 		$279K Sell
10,575
-55,540
-84% -$1.58M 0.03% 613
2024
Q1 		$2.14M Sell
66,115
-32,491
-33% -$1.19M 0.22% 139
2023
Q4 		$4.15M Buy
98,606
+53,200
+117% +$1.96M 0.48% 48
2023
Q3 		$1.74M Sell
45,406
-468
-1% -$10.6K 0.2% 134
2023
Q2 		$870K Buy
+45,874
New +$855K 0.14% 209

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Seven Eight Capital's IMVT Position: Q3 2024 in Review

Seven Eight Capital sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 10,575 shares — an estimated $279K sold.

Seven Eight Capital first reported a position in IMVT in Q2 2023 and held it in 5 quarters. The position peaked at $4.15M in Q4 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Seven Eight Capital reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 10,575 Immunovant shares in Q3 2024, an estimated $279K.
  • Seven Eight Capital first reported a position in Immunovant in Q2 2023 and held it in 5 quarters.
  • Seven Eight Capital's Immunovant position peaked at $4.15M in Q4 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.